Exelixis, Inc. will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website.

Conference Call Details

To access the conference call, participants can dial the domestic number (800) 715-9871 or the international number (646) 307-1963. The conference call ID number is 5587241. The live webcast can be accessed by logging onto www.exelixis.com and proceeding to the Event Calendar page under the Investors & News heading.

Webcast Replay

A webcast replay of the conference call will be archived on www.exelixis.com for one year following the event.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. The company is rapidly evolving its product portfolio to target an expanding range of tumor types and indications with its clinically differentiated pipeline of small molecules and biotherapeutics. This approach harnesses decades of investment in science and partnerships to advance its pipeline of franchise molecules, including the novel oral kinase inhibitor zanzalintinib, and to extend the impact of its flagship commercial product, CABOMETYX (cabozantinib).

Barclays analyst Etzer Darout has maintained an Equal-Weight rating on Exelixis (NASDAQ: EXEL) while raising the price target to $49 from $45. This adjustment reflects a revised valuation outlook for the biotechnology company. The revision comes as other firms have also recalibrated their expectations for Exelixis's stock performance.

Truist Securities analyst Gregory Renza previously maintained a Hold rating on Exelixis while raising the price target to $56 from $54. HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating with a price target of $56. These endorsements contrast with varied perspectives on the company's valuation and future performance.

Separately, Citizens analyst Silvan Turkcan maintained a Market Outperform rating and increased the price target to $55 from $50. UBS analyst Ashwani Verma has also maintained a Neutral rating on Exelixis while raising the price target to $52 from $43. These adjustments reflect a broader assessment of Exelixis's position within the sector and its potential for operational growth.

Analyst Ratings and Price Targets

The following table details the current ratings and price targets for Exelixis:

The decision to raise price targets while adjusting ratings underscores the analysts' views that Exelixis is poised for growth, albeit with varying degrees of optimism. Investors will likely monitor the company's upcoming financial results for validation of these revised targets.